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Background: Loss of TP53 function through gene mutation is a critical event in the development and progression
of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity
amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether
TP53 mutations classified as functionally inactive (£20% of wildtype transactivation ability) had different prognostic
and predictive values in CRC compared with mutations that retained significant activity.
Materials and methods: TP53 mutations within a large, international database of CRC (n = 3583) were classified
according to functional status for transactivation.
Results: Inactive TP53 mutations were found in 29% of all CRCs and were more frequent in rectal (32%) than
proximal colon (22%) tumours (P < 0.001). Higher frequencies of inactive TP53 mutations were also seen in
advanced stage tumours (P = 0.0003) and in tumours with the poor prognostic features of vascular (P = 0.006) and
lymphatic invasion (P = 0.002). Inactive TP53 mutations were associated with significantly worse outcome only in
patients with Dukes’ stage D tumours (RR = 1.71, 95%CI 1.25–2.33, P < 0.001). Patients with Dukes’ C stage
tumours appeared to gain a survival benefit from 5-fluorouracil-based chemotherapy regardless of TP53 functional
status for transactivation ability.
Conclusions: Mutations that inactivate the transactivational ability of TP53 are more frequent in advanced CRC and
are associated with worse prognosis in this stage of disease.
Key words: chemotherapy, colorectal cancer, mutation, prognosis, TP53, transactivational ability
introduction
The TP53 tumour suppressor gene encodes a 393 amino acid
transcription factor that is activated by a variety of cellular
stresses including DNA damage. The activated TP53 protein
binds to regulatory regions of downstream target genes to
initiate a programme of cell cycle arrest, DNA repair,
apoptosis and angiogenesis [1]. Loss of TP53 function is
therefore likely to be a critical event in tumourigenesis and
approximately half of all human cancers show this alteration [2].
Extensive databases on TP53 mutation reveal that more than
80% are missense mutations leading to the synthesis of stable,
full-length protein [3]. The common missense mutations
disrupt the ability of TP53 protein to bind DNA and
transactivate target genes.
A recent study investigated the functional activity of 2314
different p53 mutations in terms of their ability to transactivate
several target genes in a yeast assay [4]. The most common
TP53 mutations in human tumours show a clear loss of
transactivation activity, however more than 50% of the rarer
mutations retain significant activity [5]. Follow-up studies did
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179 mutant TP53 species and their ability to induce apoptosis
in vitro [6]. These results demonstrate that TP53 mutants
are functionally heterogeneous, thus complicating the
interpretation of prognostic and predictive data for this genetic
alteration in cancer.
The ‘CRC-p53’ International Collaborative Study has
assembled data on TP53 mutations in 3583 colorectal cancer
(CRC) patients from 25 different research groups [7]. This
database allowed evaluation of the prognostic significance of
TP53 mutation in relation to factors such as tumour site in the
large bowel and the use of adjuvant chemotherapy. In addition,
the prognostic significance of different types of TP53 mutation
including hot-spots and conserved domains was also
investigated. In the present study we examined the clinical
significance of TP53 mutations in the CRC-p53 database
following their classification according to functional activity for
transactivation as determined by in vitro assay [4].
materials and methods
CRC-p53 database
The CRC-p53 database contains information on 3583 CRC patients from 17
different countries, including TP53mutation status and survival [7]. Clinical
and pathological data include patient age and gender, tumour site, stage and
grade, lymphatic and vascular invasion, and treatment with adjuvant
chemotherapy. Cases were divided into three groups according to site of the
primary tumour (proximal colon, distal colon, sigmoid colon/rectal) due to
increasing evidence for different CRC aetiology according to site of origin in
the large bowel [8, 9]. Follow-up times (median and range) were 58 months
(1–194), 61 months (1–173) and 61 months (1–235) for patients with
proximal colon, distal colon and rectal tumours, respectively. Proximal
colon tumours were defined as originating in the caecum, ascending colon
or transverse colon. Distal colon tumours were from the splenic flexure and
descending colon, while rectal tumours included the sigmoid colon and
rectum.
functional categorisation of TP53 mutations
TP53mutation status was determined using SSCP, DGGE, TGGE and direct
DNA sequencing. DNA sequence information was available for 894 tumours
found to have mutation. These were classified into four functional categories
for transactivation activity as described earlier [5]. Compared with wildtype
TP53, these demonstrated <10% activity (category 0), 11%–20% activity
(category 1), 21%–50% activity (category 2) and >50% activity (category 3).
The ‘active TP53’ group comprised wildtype TP53 and mutation categories
2 and 3 (21%–100% activity), while the ‘inactive TP53’ group comprised
mutation categories 0 and 1 (0%–20% activity).
statistical analyses
Statistical analyses were performed separately for each of the three
subgroups of patients classified according to the site of tumour origin
(proximal colon, distal colon, sigmoid colon/rectum). Associations
between functional category of TP53 mutation (active or inactive) and
clinico-pathological variables were evaluated by the chi-squared test with
Yates correction, where appropriate. Survival time was calculated from the
date of surgery to the date of death (cancer-related causes) or last follow-up,
with times censored for patients dying from causes unrelated to CRC or
peri-operatively. Significant differences between survival curves were
evaluated by the log-rank and Wilcoxon tests or a test for trend where
appropriate. Because of the multiple statistical analyses performed, only
P values <0.01 were considered significant. All P values were two-sided.
results
A total of 2867 CRC cases were classified as having
transcriptionally active (2048, 71%) or inactive (819, 29%) TP53
according to the definition of Soussi et al. [5]. Meta-analysis of
TP53 mutations in CRC shows that all studies included in the
CRC-p53 database have a normal distribution for loss of TP53
function [5]. Associations between TP53 mutation functional
categories and clinicopathological features of CRC arising
at different sites in the large bowel are shown in Table 1. A
significantly higher frequency of inactive TP53 mutations was
seen in rectal (32%) compared with proximal colon (22%)
cancers (P < 0.001), with distal colon cancers showing an
intermediate frequency (26%). For each site, the more advanced
Dukes’ D tumours contained higher frequencies of inactive
TP53 compared with Dukes’ A–C tumours. The association
approached significance only in the proximal tumours
(P < 0.05) but was highly significant in the overall CRC cohort
(P = 0.0003). Vascular and lymphatic invasion by tumour
cells are both indicators of more aggressive disease. Similar to
advanced stage, tumours with these features showed higher
frequencies of inactive TP53 mutations. This was observed at
each site but reached significance only in the overall CRC cohort
(P = 0.006 and P = 0.002, respectively). No associations were
seen between the functional status of TP53 mutations and
patient age or histological grade. A gender difference in the
frequency of inactive TP53 mutations was observed for distal
colon tumours but not for the other sites. Mucinous tumours
at each site showed a lower frequency of inactive TP53
mutation but this reached significance only in the overall
group (P = 0.003).
Inactive TP53 mutations were examined for prognostic
significance in the overall cohort and in all site and stage
subgroups using active TP53 status as the reference group
(Table 2). No prognostic significance was seen for inactive TP53
mutations in Dukes’ A–C tumours from any of the sites or in the
overall cohort. However, the inactive TP53 mutations were
associated with significantly worse patient survival for Dukes’ D
tumours from all sites as well as those from the proximal colon
and rectum. Using wildtype TP53 status as the reference group,
the inactive TP53 mutation group again showed prognostic
significance only in Dukes’ D tumours in the overall cohort
(RR = 1.67, 95%CI 1.21–2.29, P = 0.002) as well as in the
proximal colon (RR = 2.03, 95%CI 1.10–3.76, P = 0.024) and
rectal (RR = 1.65, 95%CI 1.09–2.51, P = 0.018) tumour groups.
The small number of active TP53 mutations (n = 60) precluded
separate analysis for the prognostic significance of this group
against wildtype TP53.
The predictive value of TP53 functional status for survival
benefit from adjuvant 5-fluorouracil-based chemotherapy was
investigated in Dukes’ C patients (Table 3). For all three
tumour sites and for the overall cohort, both patient groups
with active and inactive TP53 mutation status showed better
outcome when treated with chemotherapy. The wildtype
TP53 group also showed better survival with the use of
chemotherapy (P < 0.001 for the overall group), however the
number of active TP53 mutant cases was insufficient to allow
separate analysis. The results indicate a similar level of
survival benefit from adjuvant treatment regardless of the TP53
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Table 1. Associations between functional categories of TP53 mutation
and clinicopathological features of CRC
Feature (n) Active (%) Inactive (%) P
Proximal colon (851) 666 (78) 185 (22)
Age <50 years (65) 52 (80) 13 (20)
Age 50–75 years (560) 441 (79) 119 (21)
Age >75 years (224) 173 (77) 51 (23) NS
Male (412) 315 (76) 97 (24)
Female (439) 351 (80) 88 (20) NS
Dukes’ A (44) 40 (91) 4 (9)
Dukes’ B (322) 253 (79) 69 (21)
Dukes’ C (421) 330 (78) 91 (22)
Dukes’ D (62) 42 (68) 20 (32) NS (0.038)
Histological grade G1 (107) 92 (86) 15 (14)
Histological grade G2 (515) 397 (77) 118 (23)
Histological grade G3 (201) 162 (81) 39 (19) NS
Non-mucinous (199) 143 (72) 56 (28)
Mucinous (41) 34 (83) 7 (17) NS
No vascular invasion (136) 104 (77) 32 (23)
Vascular invasion (38) 26 (68) 12 (32) NS
No lymphatic invasion (110) 87 (79) 23 (21)
Lymphatic invasion (99) 65 (66) 34 (34) NS (0.029)
Distal colon (282) 208 (74) 74 (26)
Age <50 years (28) 19 (68) 9 (32)
Age 50–75 years (188) 145 (77) 43 (23)
Age >75 years (64) 44 (69) 20 (31) NS
Male (132) 107 (81) 25 (19)
Female (149) 101 (68) 48 (32) NS (0.011)
Dukes’ A (23) 17 (74) 6 (26)
Dukes’ B (119) 93 (78) 26 (22)
Dukes’ C (115) 83 (72) 32 (28)
Dukes’ D (25) 15 (60) 10 (40) NS
Histological grade G1 (47) 34 (72) 13 (28)
Histological grade G2 (189) 143 (76) 46 (24)
Histological grade G3 (36) 24 (67) 12 (33) NS
Non-mucinous (91) 63 (69) 28 (31)
Mucinous (13) 11 (85) 2 (15) NS
No vascular invasion (80) 51 (64) 29 (36)
Vascular invasion (8) 3 (38) 5 (62) NS
No lymphatic invasion (55) 38 (69) 17 (31)
Lymphatic invasion (49) 29 (59) 20 (41) NS
Rectum (1734) 1174 (68) 560 (32)
Age <50 years (226) 157 (69) 69 (31)
Age 50–75 years (1159) 788 (68) 371 (32)
Age >75 years (346) 227 (66) 119 (34) NS
Male (968) 653 (67) 315 (33)
Female (766) 521 (68) 245 (32) NS
Dukes’ A (197) 135 (68) 62 (32)
Dukes’ B (549) 370 (67) 179 (33)
Dukes’ C (865) 599 (69) 266 (31)
Dukes’ D (113) 64 (57) 49 (43) NS
Histological grade G1 (213) 148 (69) 65 (31)
Histological grade G2 (1213) 814 (67) 399 (33)
Histological grade G3 (227) 162 (71) 65 (29) NS
Non-mucinous (504) 311 (62) 193 (38)
Mucinous (38) 29 (76) 9 (24) NS
No vascular invasion (351) 219 (62) 132 (38)
Vascular invasion (94) 46 (49) 48 (51) NS (0.018)
No lymphatic invasion (250) 149 (60) 101 (40)
Lymphatic invasion (209) 103 (49) 106 (51) NS (0.027)
Table 2. Prognostic significance for functional categories of
TP53 mutation in site and stage subgroups of colorectal cancer




Inactive (72) 1.11 0.69–1.79 NS
Dukes’ B
Active (716) 1.00
Inactive (274) 0.91 0.72–1.14 NS
Dukes’ C
Active (1012) 1.00
Inactive (389) 0.91 0.78–1.06 NS
Dukes’ D
Active (121) 1.00




Inactive (4) 1.07 0.60–1.65 NS
Dukes’ B
Active (253) 1.00
Inactive (69) 1.07 0.69–1.65 NS
Dukes’ C
Active (330) 1.00
Inactive (91) 0.81 0.59–1.10 NS
Dukes’ D
Active (42) 1.00




Inactive (6) 1.73 0.02–10.4 NS
Dukes’ B
Active (93) 1.00
Inactive (26) 1.14 0.54–2.39 NS
Dukes’ C
Active (83) 1.00
Inactive (32) 1.18 0.68–2.06 NS
Dukes’ D
Active (15) 1.00




Inactive (62) 1.02 0.59–1.74 NS
Dukes’ B
Active (370) 1.00
Inactive (179) 0.81 0.61–1.07 NS
Dukes’ C
Active (599) 1.00
Inactive (266) 0.94 0.78–1.14 NS
Dukes’ D
Active (64) 1.00
Inactive (49) 1.76 1.16–2.66 0.007
RR, relative risk; CI, confidence interval.
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functional status for transcriptional ability. The above findings
should be interpreted with caution, however, because of the
small number of cases in several subgroups and the non-
randomised nature of patient selection for chemotherapy.
discussion
Evidence for the heterogeneity of TP53 mutations with respect
to cancer patient outcomes has been available for several years
[10–13]. More recent in vitro work has quantitated the
functional activity of different TP53 mutations with respect to
their ability to transactivate target genes [4]. In the current study
we have used knowledge gained from this in vitro work to
classify TP53 mutations into active and inactive categories and
thereby determine their prognostic and predictive significance
in CRC. To do this we have taken advantage of the CRC-TP53
International Collaborative Study database containing
information on the TP53 mutation status from over 3500 CRC
patients in 17 countries [7].
Almost one-third of rectal tumours were found to contain
inactive TP53 mutations compared to just 22% for tumours
arising in the proximal colon (Table 1). The reasons for this are
unknown but may indicate a more important role for TP53
mutation in the development of rectal compared with proximal
tumours. The higher frequency of inactive TP53 mutations in
Dukes’ D (39.5%) compared with Dukes’ A–C (27.7%) tumours
suggests these specific mutations are associated with a more
aggressive phenotype. In support of this, tumours with the poor
prognosis features of vascular or lymphatic invasion also
showed significantly higher frequencies of inactive TP53
mutations in the overall CRC cohort.
An interesting finding in this study was that inactive TP53
mutations were a prognostic feature for poor survival only in
patients with Dukes’ stage D tumours (Table 2). The increased
risk of death associated with this functional category of
mutation was approximately two-fold. In contrast, no
prognostic significance was seen for inactive TP53 mutations in
any of the earlier tumour stage groups. This result cannot be
explained by an effect of chemotherapy since only a very small
proportion of Dukes’ A and B patients received this treatment.
Therefore, it appears that not only are inactive TP53 mutations
more frequent in advanced CRC, but any prognostic value is
also restricted to late stage tumours.
There was no evidence for a difference in the response of
Dukes’ C patients to adjuvant chemotherapy according to TP53
functional status (Table 3). Active and inactive TP53 groups
showed similar levels of benefit from chemotherapy, with
a Relative Risk (RR) of 0.61 and 0.63, respectively. Therefore,
the functional status of TP53 mutation for transactivation
ability does not appear to influence the response of localised
CRC to 5-fluorouracil-based adjuvant chemotherapy. This
finding requires confirmation, however, in prospective studies
where patients have been randomized to adjuvant treatments.
The better survival of adjuvant treated Dukes’ C patients in this
study may, in part, be explained by selection bias for treatment
towards a younger and healthier population.
In view of the relatively high frequency and the prognostic
significance of inactive TP53mutations in advanced CRC, it will
be interesting to determine whether these mutations have
predictive value for response to 5-fluorouracil as well as to
newer treatments such as oxaliplatin and irinotecan, which act
through different cytotoxic mechanisms. The strong and
independent prognostic significance reported for TP53
mutation in breast cancer suggests it will also be interesting to
investigate functional categories of mutation in this tumour
type, particularly since several studies on large cohorts have
already been carried out [14].
This study found that inactive TP53 mutations had no
prognostic significance in Dukes’ A–C CRC and no predictive
value in Dukes’ C CRC. However, the TP53 mutations were
defined by their in vitro transactivation ability [4, 5] and it is
possible that categorisation according to ability to induce
apoptosis would give a different result. Because of the technical
challenges involved, the apoptotic ability of different TP53
mutants remains to be determined and may in any case depend
upon the cell type. A recent study found no correlation between
the transcriptional activity of 179 mutant TP53 species and
their ability to induce apoptosis of Saos-2 cells in vitro [6]. This
study also described the existence of ‘super TP53 mutants’
with a greatly elevated capacity to induce apoptosis and which
cluster at amino acids 121 and 290–292. Unfortunately the
small number of such mutants in the present study prevented
their investigation for prognostic and predictive significance.
An alternate explanation for the lack of prognostic
significance observed for inactive TP53 mutations in localised
CRC is that such changes are important only during the very
early stages of carcinogenesis. Because of selective pressures,
other genetic and epigenetic changes may later overshadow any
Table 3. Predictive value of functional categories of TP53 mutation in
Dukes’ C colorectal cancer
Tumour site (n) RR CI (95%) P
All sites, active TP53
No chemotherapy (628) 1.00
Chemotherapy (342) 0.61 0.50–0.73 <0.001
All sites, inactive TP53
No chemotherapy (236) 1.00
Chemotherapy (121) 0.63 0.46–0.85 0.003
Proximal colon, active TP53
No chemotherapy (202) 1.00
Chemotherapy (111) 0.57 0.41–0.79 <0.001
Proximal colon, inactive TP53
No chemotherapy (56) 1.00
Chemotherapy (26) 0.42 0.21–0.85 NS
Distal colon, active TP53
No chemotherapy (50) 1.00
Chemotherapy (33) 0.53 0.26–1.09 NS
Distal colon, inactive TP53
No chemotherapy (19) 1.00
Chemotherapy (10) 0.91 0.31–2.63 NS
Rectum, active TP53
No chemotherapy (376) 1.00
Chemotherapy (198) 0.64 0.50–0.81 <0.001
Rectum, inactive TP53
No chemotherapy (161) 1.00
Chemotherapy (85) 0.68 0.47–0.97 NS
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differences in TP53 functional activity. A further possible
explanation relates to the recent discovery of an alternative
promoter and of multiple splice variants for TP53 [15]. At least
one of the isoforms, D133p53, can have a dominant negative
effect on full-length TP53 and inhibit TP53-mediated apoptosis.
The differential expression of TP53 isoforms in human tumours
could again overshadow any functional differences between
different TP53 mutants.
The TP53-CRC International Collaborative Study found
evidence for prognostic significance of exon 5 mutations in
proximal colon tumours and of denaturing mutations in distal
colon tumours [7]. That study, however, did not investigate the
prognostic significance of different TP53 mutations in relation
to tumour stage. In light of the present finding of strong
prognostic value for inactive TP53 mutations in Dukes’ D
tumours, it will be interesting to determine whether any of the
structural groups of TP53 mutation also have prognostic
significance in advanced CRC.
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